What we're reading, December 23, 2015: CMS releases data on the most expensive Medicare drugs, while HHS reports strong enrollment numbers on HealthCare.gov, and Hillary Clinton outlines a plan to spend $20 billion on Alzheimer's disease research.
CMS has released a new interactive tool with information on Medicare spending on prescription drugs for both Part B and Part D in a bid for greater transparency. The online dashboard allows consumers, policy makers, academics, and other stakeholders see the top 15 drugs by total annual cost, the top 15 drugs by highest spending per Medicare user, and the top 10 drugs with the highest annual increase in total cost in 2014 for both Part B and Part D for a total of 6 lists. There are a total of 80 drugs represented.
As the end of the year draws closer, HHS has announced that enrollment for health coverage through HealthCare.gov is up about one-third over the previous year. A total of 8.2 million consumers have signed up or had their coverage automatically renewed, reported USA Today. In addition, the government is seeing more young people sign up compared to last year, which improves the risk pool and creates a more stable insurance market. There were nearly twice as many consumers younger than 35 years who signed up before the deadline to receive coverage starting January 1, 2016.
Finally, Democratic presidential hopeful Hillary Clinton has called for increased investment in Alzheimer’s disease research. Her plan calls for $2 billion a year for the next 10 years to find a cure for Alzheimer’s. However, The Washington Post noted that Clinton did not offer specifics about where the money would come from.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen